Redoxis is a privately held company owned by founders, personnel and the investment firm Sätila MedTech AB.
Board of Directors
Malin Hultqvist Hopkins, PhD
CEO, Member of the board
Peter Olofsson, MBA, PhD
Member of the Board
Member of the board
Redoxis is a member of several programs supported by EU integrated FP7 programs. The EU funded projects are important to us allowing networking and keeping up to date with cutting edge researchers from Europe’s main universities, clinical centers and the pharma industry.
From 2015, Redoxis was also granted EUREKA status and received Eurostars funding. The Eurostars funding is supporting improvement in technical competence and will enable growth and increased capacities.